Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
- Status
- planned
- Phase
- Early Phase 1
- Institution
- Yale University
- Principal investigator
- Godfrey Pearlson, MD
- Start date
- 2026-08-10
- End date
- 2028-04-01
- Registry ID
- NCT07449351
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.